News/ News/ News/ Oncology/ R&D BMS strikes three-year cancer R&D deal with Flatiron Joy Persaud Bristol-Myers Squibb, digital health, Flatiron, Roche 0 Comment Bristol-Myers Squibb has struck a three-year with Flatiron Health that aims to make cancer R&D more efficient and Share X BMS strikes three-year cancer R&D deal with Flatiron https://pharmaphorum.com/news/bms-strikes-flatiron-deal/
Cancer/ Digital and Social Media/ News/ R&D Pfizer might buy BMS for $130bn – but should it? Andrew McConaghie BMS, digital health, Flatiron, Pfizer, Roche 0 Comment Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields Share X Pfizer might buy BMS for $130bn – but should it? https://pharmaphorum.com/news/pfizer-might-buy-bms-for-130bn-but-should-it/
Bristol-Myers Squibb, digital health, Flatiron, Roche
0 Comment
